Filed by sedaredgar.com - Acrongenomics Inc - Exhibit 10.2






[On headed paper of Molecular Vision Limited]


	Professor Donal Bradley 
Rose Garth, Old Long Grove
      
Seer Green, Beaconsfield 
Buckinghamshire HP9 2QH 
United
      Kingdom 	Professor Andrew DeMello 
64 Hamilton Road
      
Middlesex TW2 6SN 
Untied Kingdom 

	Dr John DeMello 
Flat 9, The Chase 
Clapham, London
      SW4 0NH 
United Kingdom 

	Imperial Innovations Limited 
Level 12
      Electrical Engineering Building 
Imperial College London 
London SW7
      2AZ 
United Kingdom 
0 
	Imperial Innovations Businesses LLP ("Imperial")
      
Level 12 Electrical Engineering Building 
Imperial College London
      
London SW7 2AZ 
United Kingdom 
	Acrongenomics Inc. 
("Acrongenomics")
      
Fairfax House 
15 Fulwood Place 
London WC1V 6AY 
United
      Kingdom 
	Christopher Wright 
("Mr Wright") 	




             
  2008 

Dear Sirs

Supplemental Agreement to the Subscription and Shareholders'
Agreement relating to Molecular Vision Limited (the "Company") 

This letter agreement is supplemental to the subscription and
shareholders' agreement entered into by the Company and certain of you on 30
July 2007 and adhered to by Imperial, Acrongenomics and Mr Wright on [ ], [ ]
and [ ] respectively (the "Shareholders' Agreement"). The purpose of this
letter agreement is to set out various amendments and additions to the
Shareholders' Agreement. 

Acrongenomics Inc. Board Seat Rights

Pursuant to a letter agreement dated 19 August 2008 entered
into between the Company, you and Acrongenomics, it is agreed that Acrongenomics
shall be entitled to appoint a director to the board of the Company for so long
as it holds at least 15% of the shares of the Company in issue. By signing this
letter, you agree to the insertion of the following new clauses in the
Shareholders' Agreement in the following terms:

	
      14.3A 
	
      Subject to prior approval by the Board (such approval
      not to be unreasonably withheld) of the identity of the proposed
      appointee, Acrongenomics shall be entitled to appoint (for long as
      it holds at least 15% of the Shares in issue) as a director of the
      Company any person and to remove from office any person so appointed
      and to appoint another person in his place. The appointee of
      Acrongenomics shall have the right to appoint an alternate for
      specific director meetings he/she cannot attend.









	14.5A 	
      Any person nominated under Clause 14.3A who is not an
      employee of Acrongenomics or its group shall on his appointment as
      a Director, enter into a non-executive letter of appointment with
      the Company on terms reasonably acceptable to the Board and
      Acrongenomics and shall also enter into a non-disclosure agreement with
      the Company on terms reasonably acceptable to the Board and
      Acrongenomics. 

	  	
       

	14.6A 	
      Acrongenomics. shall remove a Director appointed under
      this Clause 14 in circumstances where Acrongenomics. ceases to
      holdat least 15% of the Shares in issue. 

	  	
       

	14.7A 	
      The Company, for so long as Acrongenomics. is entitled
      to appoint a Director under Clause 14.3A, shall send to
      Acrongenomics. copies of all Board and committee papers at the same
      time as they are sent to the Directors or the members of the relevant
      committee. 



The following definition shall be inserted in clause 1.1 of the
Shareholders' Agreement:

"Acrongenomics" means Acrongenomics Inc. , a
company organised pursuant to the laws of the State of Nevada and having an
office at Fairfax House, 15 Fulwood Place, London, WC1V 6AY, United
Kingdom.

Please can you signify your consent and agreement to the
changes referred to at paragraphs 1 and 2 above by signing and dating it below
and returning to us at the address at the head of this letter a copy of this
letter. 

To clarify, however, the consent and agreement to be given by
you (or deemed to have been given by you) as regards variations to the
Shareholders' Agreement is for the matters referred to above only, and shall not
apply to any other variation of the Shareholders' Agreement. 

Yours faithfully,

For and on behalf of Molecular Vision Limited

 

 

On a copy of this letter:

We hereby consent and agree to the variations to the
Shareholders' Agreement proposed by this letter.





	....................................... 
	Professor Donal Bradley 
	....................................... 
	Professor Andrew DeMello 
	........................................ 
	Dr John DeMello 
	........................................ 
	Imperial Innovations Limited 
	........................................ 
	Imperial Innovations Businesses Limited Liability
      Partnership 
	........................................ 
	Acrogenomics Inc. 
	........................................ 
	Christopher Wright